A Randomized, Double Blind Pilot Study Evaluating CLCNKA Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Eplerenone (Primary)
- Indications Hypertension; Left ventricular hypertrophy
- Focus Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 19 Jan 2011 New trial record